KNMEDIUM SIGNALFINANCIAL10-K

KN executed substantial balance sheet deleveraging while improving operating performance, reducing debt by $88.5M and cash by $75.9M through what appears to be debt paydown and share repurchases.

The company appears to be in a strengthening financial position, with operating income growing meaningfully to $70.3M while simultaneously reducing total debt by 44% to $114M. The strategic use of cash reserves for debt reduction and increased share buybacks ($65M vs $53.7M) suggests management confidence in the business trajectory and commitment to optimizing capital structure.

Comparing 2026-02-09 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

KN demonstrated solid operational improvement with operating income rising 36% to $70.3M, while strategically deploying cash reserves for balance sheet optimization. The company reduced total debt by $88.5M to $114M and current liabilities by $91.7M, funded primarily through a $75.9M reduction in cash reserves and continued share repurchase activity totaling $65M. This reflects a deliberate deleveraging strategy that strengthens the financial foundation while maintaining operational momentum.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-58.3%
$130.1M$54.2M

Cash declined 58.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
-46.4%
$197.6M$105.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Debt
Balance Sheet
-43.7%
$202.5M$114.0M

Debt reduced 43.7% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Income
P&L
+35.7%
$51.8M$70.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Share Buybacks
Cash Flow
+21%
$53.7M$65.0M

Share repurchases increased 21% — management returning capital, signals confidence in intrinsic value.

Current Assets
Balance Sheet
-19.4%
$361.4M$291.4M

Current assets declined 19.4% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-02-09
PRIOR — 2025-02-13
ADDED
The number of outstanding shares of the registrant s common stock as of February 5, 2026 was 84,913,639 .
Through extreme reliability, custom engineering, and scalable manufacturing, our high-performance capacitors, radio frequency ( RF ) filters, advanced microphones, and balanced armature speakers enable and enhance the most demanding applications across medtech, defense, industrial, and electrification/energy markets with the power to change, improve, and save lives.
Our Strategy The Company is focused on leveraging its unique technologies to design custom engineered solutions and then deliver them at scale for customers in high growth markets that value our solutions.
Our reportable segments are as follows: PD Segment Our PD segment specializes in the custom design and delivery of high performance capacitor products and RF solutions primarily serving the defense, industrial, medtech, and electrification/energy markets.
MSA Segment Our MSA segment designs and manufactures balanced armature speakers and microphones used in hearing health and specialty audio applications that serve the medtech and industrial markets.
We sell our products directly to original equipment manufacturers ("OEMs") and through sales representatives and distributors worldwide.
Many suppliers that provide technical, engineering, and manufacturing services for the defense sector are located in, or have facilities located in, countries that are viewed as potential strategic adversaries.
As a result, there is a rising demand for supply partners throughout the value chain that can reliably and rapidly deliver custom solutions with strong domestic manufacturing footprints.
Within PD, the demand for high performance capacitors, including specialty film, is seeing potentially large growth as alternative technologies emerge to address the accelerating demand for power.
The trend toward domestic manufacturing footprints in the PD segment is amplified and extends across many of the markets we serve by the recent rise of trade barriers, including tariffs, as companies seek to mitigate the effect on their costs and the prices passed through to their customers.
REMOVED
The number of outstanding shares of the registrant s common stock as of February 11, 2025 was 87,663,173 .
Our high-performance capacitors, radio frequency ("RF") and microwave filters, advanced medtech microphones, balanced armature speakers, and miniaturization products enable and enhance the performance of technologies with the power to change, improve, and save lives.
Our Strategy The Company is focused on delivering high value, differentiated solutions to a diverse set of end markets.
Our expertise in the traditional hearing aid market enables us to capitalize on emerging markets like Over the Counter ("OTC") hearing aids.
Our reportable segments are as follows: PD Segment Our PD segment specializes in the design and delivery of high performance capacitor products and RF solutions primarily serving the defense, medtech, electrification, and industrial markets.
MSA Segment Our MSA segment designs and manufactures balanced armature speakers and microphones used in applications that serve the hearing health and premium audio markets.
We sell our products directly to original equipment manufacturers ("OEMs"), their contract manufacturers and suppliers, and through sales representatives and distributors worldwide.
Portions of this segment face much greater exposure to capital investment cycles and government spending, both direct and indirect, as some of these end markets are largely dependent on project upgrades, expansion, and government contracts.
We have been experiencing increased demand for our products driven by the upgrading of large rotary radar and deployment of communication satellites.
In addition, demand has increased as a result of the expansion of small implantable devices to monitor and correct a host of chronic health issues.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →